Global Prostate Cancer Testing
Global Prostate Cancer Testing

Prostate Cancer Testing Comprehensive Study by Type (PSA Tests, CTC Tests, Immunohistochemistry, PCA3 Tests, Others), Application (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others) Players and Region - Global Market Outlook to 2024

Prostate Cancer Testing Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 247 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Prostate Cancer Testing Market Study:
Genomic Health (United States), OPKO (United States), Siemens Healthcare (Germany), DiaSorin (Italy), BioMeriux (France), Roche (Switzerland), MDx Health (Belgium), Beckman Coulter (United States), Myriad Genetics (United States) and Ambry Genetics (United States)

In the last few years, Global market of Prostate Cancer Testing developed rapidly. Major factors driving the market are Increase Prevalence of Prostate Cancer .

On the basis of product type, the Prostate Cancer Testing market is segmented by PSA Tests, CTC Tests, Immunohistochemistry, PCA3 Tests and Others.

On the basis of applications, the Prostate Cancer Testing market is segmented by Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes and Others.

Europe is the second largest market after North America for Prostate Cancer Testing

Recent Industry Highlights:
In July 2019, MDNA Life Sciences launched a new prostate cancer test in United Kingdom, which is beneficial in providing diagnostic tests of individuals and strengthening its product portfolio by introducing the new Mitomic Prostate Test (MPT) for clinical use..

.

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Prostate Cancer Testing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Prostate Cancer Testing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Prostate Cancer Testing Manufacturers, Prostate Cancer Testing Traders, End-Use Market Participants of Different Segments of Prostate Cancer Testing, Government and Research Organizations, R&D Institutions and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • PSA Tests
  • CTC Tests
  • Immunohistochemistry
  • PCA3 Tests
  • Others
By Application
  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase Prevalence of Prostate Cancer
      • 3.2.2. Growing Awareness Regarding the Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
      • 3.3.2. Stiff Competition between Major Players
    • 3.4. Market Trends
      • 3.4.1. Increasing demand at Asia Pacific region
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Prostate Cancer Testing, by Type, Application and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Prostate Cancer Testing (Value)
      • 5.2.1. Global Prostate Cancer Testing by: Type (Value)
        • 5.2.1.1. PSA Tests
        • 5.2.1.2. CTC Tests
        • 5.2.1.3. Immunohistochemistry
        • 5.2.1.4. PCA3 Tests
        • 5.2.1.5. Others
      • 5.2.2. Global Prostate Cancer Testing by: Application (Value)
        • 5.2.2.1. Hospital Associated Labs
        • 5.2.2.2. Independent Diagnostic Laboratories
        • 5.2.2.3. Cancer Research Institutes
        • 5.2.2.4. Others
      • 5.2.3. Global Prostate Cancer Testing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Prostate Cancer Testing (Price)
      • 5.3.1. Global Prostate Cancer Testing by: Type (Price)
  • 6. Prostate Cancer Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Genomic Health (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. OPKO (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Siemens Healthcare (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. DiaSorin (Italy)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BioMeriux (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MDx Health (Belgium)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Beckman Coulter (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Myriad Genetics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ambry Genetics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Prostate Cancer Testing Sale, by Type, Application and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Prostate Cancer Testing (Value)
      • 7.2.1. Global Prostate Cancer Testing by: Type (Value)
        • 7.2.1.1. PSA Tests
        • 7.2.1.2. CTC Tests
        • 7.2.1.3. Immunohistochemistry
        • 7.2.1.4. PCA3 Tests
        • 7.2.1.5. Others
      • 7.2.2. Global Prostate Cancer Testing by: Application (Value)
        • 7.2.2.1. Hospital Associated Labs
        • 7.2.2.2. Independent Diagnostic Laboratories
        • 7.2.2.3. Cancer Research Institutes
        • 7.2.2.4. Others
      • 7.2.3. Global Prostate Cancer Testing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Prostate Cancer Testing (Price)
      • 7.3.1. Global Prostate Cancer Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Prostate Cancer Testing: by Type(USD Million)
  • Table 2. Prostate Cancer Testing PSA Tests , by Region USD Million (2013-2018)
  • Table 3. Prostate Cancer Testing CTC Tests , by Region USD Million (2013-2018)
  • Table 4. Prostate Cancer Testing Immunohistochemistry , by Region USD Million (2013-2018)
  • Table 5. Prostate Cancer Testing PCA3 Tests , by Region USD Million (2013-2018)
  • Table 6. Prostate Cancer Testing Others , by Region USD Million (2013-2018)
  • Table 7. Prostate Cancer Testing: by Application(USD Million)
  • Table 8. Prostate Cancer Testing Hospital Associated Labs , by Region USD Million (2013-2018)
  • Table 9. Prostate Cancer Testing Independent Diagnostic Laboratories , by Region USD Million (2013-2018)
  • Table 10. Prostate Cancer Testing Cancer Research Institutes , by Region USD Million (2013-2018)
  • Table 11. Prostate Cancer Testing Others , by Region USD Million (2013-2018)
  • Table 12. South America Prostate Cancer Testing, by Country USD Million (2013-2018)
  • Table 13. South America Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 14. South America Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 15. Brazil Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 16. Brazil Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 17. Argentina Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 18. Argentina Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 19. Rest of South America Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 20. Rest of South America Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 21. Asia Pacific Prostate Cancer Testing, by Country USD Million (2013-2018)
  • Table 22. Asia Pacific Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 23. Asia Pacific Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 24. China Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 25. China Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 26. Japan Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 27. Japan Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 28. India Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 29. India Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 30. South Korea Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 31. South Korea Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 32. Taiwan Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 33. Taiwan Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 34. Australia Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 35. Australia Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 36. Rest of Asia-Pacific Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 37. Rest of Asia-Pacific Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 38. Europe Prostate Cancer Testing, by Country USD Million (2013-2018)
  • Table 39. Europe Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 40. Europe Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 41. Germany Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 42. Germany Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 43. France Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 44. France Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 45. Italy Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 46. Italy Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 47. United Kingdom Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 48. United Kingdom Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 49. Netherlands Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 50. Netherlands Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 51. Rest of Europe Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 52. Rest of Europe Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 53. MEA Prostate Cancer Testing, by Country USD Million (2013-2018)
  • Table 54. MEA Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 55. MEA Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 56. Middle East Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 57. Middle East Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 58. Africa Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 59. Africa Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 60. North America Prostate Cancer Testing, by Country USD Million (2013-2018)
  • Table 61. North America Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 62. North America Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 63. United States Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 64. United States Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 65. Canada Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 66. Canada Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 67. Mexico Prostate Cancer Testing, by Type USD Million (2013-2018)
  • Table 68. Mexico Prostate Cancer Testing, by Application USD Million (2013-2018)
  • Table 69. Prostate Cancer Testing: by Type(USD/Units)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Prostate Cancer Testing: by Type(USD Million)
  • Table 81. Prostate Cancer Testing PSA Tests , by Region USD Million (2019-2024)
  • Table 82. Prostate Cancer Testing CTC Tests , by Region USD Million (2019-2024)
  • Table 83. Prostate Cancer Testing Immunohistochemistry , by Region USD Million (2019-2024)
  • Table 84. Prostate Cancer Testing PCA3 Tests , by Region USD Million (2019-2024)
  • Table 85. Prostate Cancer Testing Others , by Region USD Million (2019-2024)
  • Table 86. Prostate Cancer Testing: by Application(USD Million)
  • Table 87. Prostate Cancer Testing Hospital Associated Labs , by Region USD Million (2019-2024)
  • Table 88. Prostate Cancer Testing Independent Diagnostic Laboratories , by Region USD Million (2019-2024)
  • Table 89. Prostate Cancer Testing Cancer Research Institutes , by Region USD Million (2019-2024)
  • Table 90. Prostate Cancer Testing Others , by Region USD Million (2019-2024)
  • Table 91. South America Prostate Cancer Testing, by Country USD Million (2019-2024)
  • Table 92. South America Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 93. South America Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 94. Brazil Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 95. Brazil Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 96. Argentina Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 97. Argentina Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 98. Rest of South America Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 99. Rest of South America Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 100. Asia Pacific Prostate Cancer Testing, by Country USD Million (2019-2024)
  • Table 101. Asia Pacific Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 102. Asia Pacific Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 103. China Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 104. China Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 105. Japan Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 106. Japan Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 107. India Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 108. India Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 109. South Korea Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 110. South Korea Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 111. Taiwan Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 112. Taiwan Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 113. Australia Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 114. Australia Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 115. Rest of Asia-Pacific Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 116. Rest of Asia-Pacific Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 117. Europe Prostate Cancer Testing, by Country USD Million (2019-2024)
  • Table 118. Europe Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 119. Europe Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 120. Germany Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 121. Germany Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 122. France Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 123. France Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 124. Italy Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 125. Italy Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 126. United Kingdom Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 127. United Kingdom Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 128. Netherlands Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 129. Netherlands Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 130. Rest of Europe Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 131. Rest of Europe Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 132. MEA Prostate Cancer Testing, by Country USD Million (2019-2024)
  • Table 133. MEA Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 134. MEA Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 135. Middle East Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 136. Middle East Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 137. Africa Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 138. Africa Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 139. North America Prostate Cancer Testing, by Country USD Million (2019-2024)
  • Table 140. North America Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 141. North America Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 142. United States Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 143. United States Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 144. Canada Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 145. Canada Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 146. Mexico Prostate Cancer Testing, by Type USD Million (2019-2024)
  • Table 147. Mexico Prostate Cancer Testing, by Application USD Million (2019-2024)
  • Table 148. Prostate Cancer Testing: by Type(USD/Units)
  • Table 149. Research Programs/Design for This Report
  • Table 150. Key Data Information from Secondary Sources
  • Table 151. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Prostate Cancer Testing: by Type USD Million (2013-2018)
  • Figure 5. Global Prostate Cancer Testing: by Application USD Million (2013-2018)
  • Figure 6. South America Prostate Cancer Testing Share (%), by Country
  • Figure 7. Asia Pacific Prostate Cancer Testing Share (%), by Country
  • Figure 8. Europe Prostate Cancer Testing Share (%), by Country
  • Figure 9. MEA Prostate Cancer Testing Share (%), by Country
  • Figure 10. North America Prostate Cancer Testing Share (%), by Country
  • Figure 11. Global Prostate Cancer Testing: by Type USD/Units (2013-2018)
  • Figure 12. Global Prostate Cancer Testing share by Players 2018 (%)
  • Figure 13. Global Prostate Cancer Testing share by Players (Top 3) 2018(%)
  • Figure 14. Global Prostate Cancer Testing share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Genomic Health (United States) Revenue, Net Income and Gross profit
  • Figure 17. Genomic Health (United States) Revenue: by Geography 2018
  • Figure 18. OPKO (United States) Revenue, Net Income and Gross profit
  • Figure 19. OPKO (United States) Revenue: by Geography 2018
  • Figure 20. Siemens Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Siemens Healthcare (Germany) Revenue: by Geography 2018
  • Figure 22. DiaSorin (Italy) Revenue, Net Income and Gross profit
  • Figure 23. DiaSorin (Italy) Revenue: by Geography 2018
  • Figure 24. BioMeriux (France) Revenue, Net Income and Gross profit
  • Figure 25. BioMeriux (France) Revenue: by Geography 2018
  • Figure 26. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Roche (Switzerland) Revenue: by Geography 2018
  • Figure 28. MDx Health (Belgium) Revenue, Net Income and Gross profit
  • Figure 29. MDx Health (Belgium) Revenue: by Geography 2018
  • Figure 30. Beckman Coulter (United States) Revenue, Net Income and Gross profit
  • Figure 31. Beckman Coulter (United States) Revenue: by Geography 2018
  • Figure 32. Myriad Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 33. Myriad Genetics (United States) Revenue: by Geography 2018
  • Figure 34. Ambry Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 35. Ambry Genetics (United States) Revenue: by Geography 2018
  • Figure 36. Global Prostate Cancer Testing: by Type USD Million (2019-2024)
  • Figure 37. Global Prostate Cancer Testing: by Application USD Million (2019-2024)
  • Figure 38. South America Prostate Cancer Testing Share (%), by Country
  • Figure 39. Asia Pacific Prostate Cancer Testing Share (%), by Country
  • Figure 40. Europe Prostate Cancer Testing Share (%), by Country
  • Figure 41. MEA Prostate Cancer Testing Share (%), by Country
  • Figure 42. North America Prostate Cancer Testing Share (%), by Country
  • Figure 43. Global Prostate Cancer Testing: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Genomic Health (United States)
  • OPKO (United States)
  • Siemens Healthcare (Germany)
  • DiaSorin (Italy)
  • BioMeriux (France)
  • Roche (Switzerland)
  • MDx Health (Belgium)
  • Beckman Coulter (United States)
  • Myriad Genetics (United States)
  • Ambry Genetics (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation